R&D channel feed – Endpoints News

R&D channel feed

Lilly’s bimagrumab boosts weight and fat loss when added to Novo's Wegovy

3 weeks ago

Updated: Compass claims Phase 3 win in depression for psilocybin drug, yet stock plummets

3 weeks ago

Updated: A puzzling update from Novo Nordisk and new data from Roche at #ADA25

3 weeks ago

Vertex's diabetes cell therapy allows 10 patients to come off insulin

3 weeks ago

Inside the FDA’s ‘listening’ tour: Officials agree US lags behind China on drug development

3 weeks ago

Zealand study shows higher GLP-1/GLP-2 doses may lead to greater weight loss

3 weeks ago

Q&A: New BIO chair to steer industry through ‘existential threats’ despite FDA receptivity

3 weeks ago

BioNTech stops making cell therapy at Maryland site after dropping germ cell tumor indication

3 weeks ago

How a tailored ALS drug could help broaden rare disease therapies

3 weeks ago

Scholar Rock’s muscle-preserving obesity drug add-on looks competitive

3 weeks ago

Lyell’s lymphoma data for recently acquired CAR-T receive lukewarm reception on Wall Street

4 weeks ago

Mineralys gets a mid-stage win in hypertension patients with poor renal function

4 weeks ago

Dyne pivots on primary endpoint, delays filing for DM1 drug

4 weeks ago

Immuneering says MEK pill beats standard of care in first-line pancreatic cancer

4 weeks ago

Fired vaccine advisors defend ACIP’s work, independence in joint editorial

4 weeks ago

AbbVie’s cancer drug fails Phase 3 combo study to treat other bone marrow diseases

4 weeks ago

Roche moves ahead with Phase 3 Parkinson’s study despite mixed trial results

4 weeks ago

Lilly posts encouraging early-stage weight loss data on amylin candidate

4 weeks ago

Gilead, Arcellx continue to spotlight safety of multiple myeloma cell therapy

4 weeks ago

Sarepta halts Duchenne gene therapy in some patients after second death

4 weeks ago

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

4 weeks ago

Novo Nordisk plans Phase 3 trials of oral, injectable amycretin for early 2026

4 weeks ago

Exclusive: Kennedy picks for vaccine advisory board were paid experts against Merck in civil cases

4 weeks ago

Insmed aims to raise $750M in one of the largest stock offerings this year

4 weeks ago

First page Previous page 1 234 5 6 Next page Last page